Exelixis delays zanzalintinib FDA decision after major amendment

The key change is a three-month regulatory delay. The FDA moved the action date for zanzalintinib in combination with atezolizumab to March 3, 2027. 〔0〕 The prior standing date was December 3, 2026, so the filing pushes out a potentially important approval catalyst by one quarter.

The delay reflects additional FDA scrutiny, not a routine scheduling change. Exelixis says it submitted updated safety and efficacy data in response to an FDA information request, and the agency deemed that submission a major amendment. 〔1〕 That raises uncertainty around the application relative to the previously expected review timeline, even though the filing does not disclose a specific safety concern or indicate that the application is headed for rejection.

Versus what was already expected, this is a modest negative read. The direction of the event is clear: the approval decision and any launch-related contribution arrive later than the market’s prior timetable. The filing contains no new efficacy result, approval, or commercial guidance to offset the timing setback, so the net takeaway is a delayed catalyst rather than a changed clinical thesis.